NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Provided By PR Newswire

Last update: Sep 3, 2024

CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Tuesday, September 10, at 1:30 pm ET, during the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York.